

Value IN HEALTH REGIONAL ISSUES

VOLUME 2

NUMBER 2

SEPTEMBER/OCTOBER 2013

TABLE OF CONTENTS

EDITORIAL

- 169 Further Steps in the Development of Pharmacoeconomics, Outcomes Research, and Health Technology Assessment in Central and Eastern Europe, Western Asia, and Africa**
Dan Greenberg, Imre Boncz, Zoltán Kaló, and Mohamed Izham B. Mohamed Ibrahim

ECONOMIC EVALUATION

- 171 Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation in Turkey: A Microsimulation Approach**
Mete Saylan, M.J. Treur, R. Postema, N. Dilbaz, H. Savas, B.M. Heeg, and P.B. Drost
- 181 Cost-Utility Analysis of Depot Atypical Antipsychotics for Chronic Schizophrenia in Croatia**
Vlado Jukic, Miro Jakovljevic, Igor Filipcic, Miroslav Herceg, Ante Silic, Tatjana Tomljanovic, Roman Zilbershtein, Rasmus C.D. Jensen, Michiel E.H. Hemels, and Thomas R. Einarson
- 189 Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes**
Maxwell O. Adibe, Cletus N. Aguwa, and Chinwe V. Ukwé
- 199 Economic Burden of Cardiovascular Diseases in the Russian Federation**
Anna Kontsevaya, Anna Kalinina, and Rafael Oganov
- 205 Cost for Treatment of Chronic Lymphocytic Leukemia in Specialized Institutions of Ukraine**
Olena Mandrik, Isaac Corro Ramos, Olga Zalis'ka, Andriy Gaisenko, and Johan L. Severens
- 210 Costs of Medically Attended Acute Gastrointestinal Infections: The Polish Prospective Healthcare Utilization Survey**
Marcin Czech, Magdalena Rosinska, Justyna Rogalska, Ewa Staszewska, and Pawel Stefanoff
- 218 Radiology Services Costs and Utilization Patterns Estimates in Southeastern Europe—A Retrospective Analysis from Serbia**
Mihajlo Jakovljevic, Ana Rankovic, Nemanja Rančić, Mirjana Jovanović, Miloš Ivanović, Olgica Gajović, and Zorica Lazić
- 226 Children Hospitalized for Varicella: Complications and Cost Burden**
Ozden Turel, Mustafa Bakir, Ismail Gonen, Nevin Hatipoglu, Cigdem Aydogmus, Emine Hosaf, and Rengin Siraneci

PATIENT-REPORTED OUTCOMES

- 231 The Methodological Challenges for the Estimation of Quality of Life in Children for Use in Economic Evaluation in Low-Income Countries**
Travor Mabugu, Paul Revill, and Bernard van den Berg
- 240 The Impact of Pharmaceutical Care Intervention on the Quality of Life of Nigerian Patients Receiving Treatment for Type 2 Diabetes**
Maxwell O. Adibe, Chinwe V. Ukwé, and Cletus N. Aguwa

TABLE OF CONTENTS - continued

248 An Audit of Diabetes-Dependent Quality of Life (ADDQOL) in Older Patients with Diabetes Mellitus Type 2 in Slovenia

Eva Turk, Valentina Prevolnik Rupel, Alojz Tapajner, Stephen Leyshon, and Arja Isola

254 Patient-Reported Quality of Life During Antiretroviral Therapy in a Nigerian Hospital

Azuka C. Oparah, Jeffrey S. Soni, Herbert I. Arinze, and Ifeanyi E. Chiazor

CLINICAL OUTCOMES STUDIES

259 Clinical Burden of Invasive Pneumococcal Disease in Selected Developing Countries

Namaitijiang Maimaiti, Zafar Ahmed, Zaleha Md Isa, Hasanain Faisal Ghazi, and Syed Aljunid

HEALTH POLICY ANALYSIS

264 Capacity Building for HTA Implementation in Middle-Income Countries: The Case of Hungary

Zoltán Kaló, József Bodrogi, Imre Boncz, Csaba Dózsa, Gabriella Jóna, Rita Kövi, Zsolt Pásztélyi, and Balázs Sinkovits, on behalf of ISPOR Hungary Chapter

267 What Influences Recommendations Issued by the Agency for Health Technology Assessment in Poland? A Glimpse Into Decision Makers' Preferences

Maciej Niewada, Małgorzata Polkowska, Michał Jakubczyk, and Dominik Golicki

273 A Framework for Applying Health Technology Assessment in Cyprus: Thoughts, Success Stories, and Recommendations

Panagiotis Petrou and Michalis A. Talias

279 Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future?

Emmanuel Ankrah Odame

284 Dossier System as a Practical Tool for Compiling Reimbursement Lists

Maria V. Sura and Vitaly V. Omelyanovskiy

290 Impact of the Pharma Economic Act on Diffusion of Innovation and Reduction of Costs in the Hungarian Prescription Drug Market (2007–2010)

Rok Hren

300 Performance Assessment of Ga District Mutual Health Insurance Scheme, Greater Accra Region, Ghana

Eric Nsiah-Boateng and Moses Aikins

306 The Process of Privatization of Health Care Provision in Poland

Krzysztof Kaczmarek, Hannah Flynn, Edyta Letka-Paralusz, Krzysztof Krajewski-Siuda, and Christian A. Gericke

312 Transforming Public Servants' Health Care Organization in Greece through the Implementation of an Electronic Referral Project

Kyriakos Souliotis, Vasiliki Mantzana, and Manto Papageorgiou

CONCEPTUAL PAPER

319 Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt

Gihan H. Elsisy, Zoltán Kaló, Randa Eldessouki, Mahmoud D. Elmahdawy, Amr Saad, Samah Ragab, Amr M. Elshalakani, and Sherif Abaza

TABLE OF CONTENTS - continued

328 Note from the Editors

329 Erratum

LETTERS TO THE EDITORS

331 Response to “Potential Regulatory and Commercial Environment for Biosimilars in Latin America” by Azevedo et al.

333 Response to Letter from Dr. Jorge Revilla Beltri dated 22nd March, 2013

I Guide for Authors